Status:
COMPLETED
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, non-interventional study conducted in CP-CML patients receiving dasatinib who are enrolled by a sample of hematologists in France.
Eligibility Criteria
Inclusion
- Patients aged greater than or equal to 18 years
- Patients diagnosed with CP-CML
- Patients who started dasatinib within the last month before inclusion, or on the day of inclusion or within the month after inclusion
Exclusion
- Patients participating in an ongoing interventional trial
- Patients diagnosed with AP-CML (accelerated phase) or BP-CML (blast phase)
Key Trial Info
Start Date :
April 21 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 16 2020
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT04089839
Start Date
April 21 2016
End Date
January 16 2020
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Paris, France, 75002